Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether increasing the use of finger-stick point-of-care testing for hepatitis C virus HCV infection can improve diagnosis and treatment rates. The study is observational and focuses on people at risk for HCV infection who access services such as drug treatment clinics, needle and syringe programs, homelessness support, mental health services, prisons, and mobile outreach. The goal is to support national and state strategies aiming to eliminate HCV by 2030 by improving testing and treatment uptake. Participants will be offered point-of-care HCV RNA testing through finger-stick blood samples at various service sites. This testing approach allows for quicker diagnosis by reducing the need for multiple clinic visits. The program includes training for operators, quality assurance, and logistics for scaling up testing across different community health settings. Participants do not receive treatment within the study but those testing positive for HCV RNA will be connected to standard care for further assessment and treatment. During the study, participants will undergo point-of-care testing, and data will be collected on testing acceptance, HCV prevalence, and treatment initiation and completion. Researchers will measure the proportion of infected participants who start treatment within 12 weeks and track treatment outcomes up to 12 months. The study will run until 2029, and participants involvement focuses on testing and monitoring outcomes rather than receiving study treatments directly.